Literature DB >> 16966412

Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.

Philip Bejon1, Sheila Keating, Jedidah Mwacharo, Oscar K Kai, Susanna Dunachie, Michael Walther, Tamara Berthoud, Trudie Lang, Judy Epstein, Daniel Carucci, Philippe Moris, Joe Cohen, Sarah C Gilbert, Norbert Peshu, Kevin Marsh, Adrian V S Hill.   

Abstract

Two different cell populations respond to potent T-cell-inducing vaccinations. The induction and loss of effector cells can be seen using an ex vivo enzyme-linked immunospot (ELISPOT) assay, but the more durable resting memory response is demonstrable by a cultured ELISPOT assay. The relationship of the early effector response to durable resting memory is incompletely understood. Effector phenotype is usually identified by gamma interferon (IFN-gamma) production, but interleukin-2 (IL-2) has been specifically linked to the differentiation of memory cells. Here, IFN-gamma- and IL-2-secreting effector cells were identified by an ex vivo ELISPOT assay 1 week after vaccination and compared with the resting memory responses detected by a cultured ELISPOT assay 3 months later. The different kinetics and induction of IL-2 by different vaccines and natural exposure are described. Furthermore, both early IFN-gamma and IL-2 production independently predicted subsequent memory responses at 3 months in malaria-naïve volunteers, but only IFN-gamma predicted memory in malaria-exposed volunteers. However, dual ELISPOT assays were also performed on malaria-exposed volunteers to identify cells producing both cytokines simultaneously. This demonstrated that double-cytokine-producing cells were highly predictive of memory. This assay may be useful in predicting vaccinations most likely to generate stable, long-term memory responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966412      PMCID: PMC1695504          DOI: 10.1128/IAI.00774-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

Authors:  A Lalvani; P Moris; G Voss; A A Pathan; K E Kester; R Brookes; E Lee; M Koutsoukos; M Plebanski; M Delchambre; K L Flanagan; C Carton; M Slaoui; C Van Hoecke; W R Ballou; A V Hill; J Cohen
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

2.  HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Authors:  Simone C Zimmerli; Alexandre Harari; Cristina Cellerai; Florence Vallelian; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-04       Impact factor: 11.205

3.  A protein particle vaccine containing multiple malaria epitopes.

Authors:  S C Gilbert; M Plebanski; S J Harris; C E Allsopp; R Thomas; G T Layton; A V Hill
Journal:  Nat Biotechnol       Date:  1997-11       Impact factor: 54.908

4.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Authors:  J A Stoute; M Slaoui; D G Heppner; P Momin; K E Kester; P Desmons; B T Wellde; N Garçon; U Krzych; M Marchand
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

Review 5.  Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections.

Authors:  D L Doolan; S L Hoffman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

6.  Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals.

Authors:  D Herrington; J Davis; E Nardin; M Beier; J Cortese; H Eddy; G Losonsky; M Hollingdale; M Sztein; M Levine
Journal:  Am J Trop Med Hyg       Date:  1991-11       Impact factor: 2.345

7.  Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

Authors:  Judith E Epstein; Yupin Charoenvit; Kent E Kester; Ruobing Wang; Rhonda Newcomer; Steve Fitzpatrick; Thomas L Richie; Nadia Tornieporth; D Gray Heppner; Chris Ockenhouse; Victoria Majam; Carolyn Holland; Esteban Abot; Harini Ganeshan; Mara Berzins; Trevor Jones; C Nicole Freydberg; Jennifer Ng; Jon Norman; Daniel J Carucci; Joe Cohen; Stephen L Hoffman
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

8.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Authors:  Daniel P Webster; Susanna Dunachie; Jenni M Vuola; Tamara Berthoud; Sheila Keating; Stephen M Laidlaw; Samuel J McConkey; Ian Poulton; Laura Andrews; Rikke F Andersen; Philip Bejon; Geoff Butcher; Robert Sinden; Michael A Skinner; Sarah C Gilbert; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

9.  Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Authors:  Jenni M Vuola; Sheila Keating; Daniel P Webster; Tamara Berthoud; Susanna Dunachie; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

10.  CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

Authors:  Roberto C Arduino; Esteban C Nannini; Maria Rodriguez-Barradas; Shannon Schrader; Marcelo Losso; Kiat Ruxrungtham; Maria C Allende; Sean Emery; Lisa Fosdick; James Neaton; Jorge A Tavel; Richard T Davey; H Clifford Lane
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

View more
  14 in total

1.  Detection of human papillomavirus type 16-specific T lymphocytes by a recombinant vaccinia virus-based enzyme-linked immunospot assay.

Authors:  Kevin H Kim; William Greenfield; Ezekiel Shotts; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2007-02-21

2.  Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.

Authors:  Maria Cecilia Huaman; Gregory E D Mullen; Carole A Long; Siddhartha Mahanty
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

3.  Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Authors:  S Pichyangkul; U Kum-Arb; K Yongvanitchit; A Limsalakpetch; M Gettayacamin; D E Lanar; L A Ware; V A Stewart; D G Heppner; P Mettens; J D Cohen; W R Ballou; M M Fukuda
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

4.  Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.

Authors:  Nathan W Schmidt; Rebecca L Podyminogin; Noah S Butler; Vladimir P Badovinac; Brad J Tucker; Keith S Bahjat; Peter Lauer; Arturo Reyes-Sandoval; Claire L Hutchings; Anne C Moore; Sarah C Gilbert; Adrian V Hill; Lyric C Bartholomay; John T Harty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

5.  The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.

Authors:  Philip Bejon; Jedidah Mwacharo; Oscar Kai; Stephen Todryk; Sheila Keating; Brett Lowe; Trudie Lang; Tabitha W Mwangi; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

6.  Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).

Authors:  Selidji T Agnandji; Rolf Fendel; Michaël Mestré; Michel Janssens; Johan Vekemans; Jana Held; Ferdinand Gnansounou; Sonja Haertle; Isabel von Glasenapp; Sunny Oyakhirome; Ludovic Mewono; Philippe Moris; Marc Lievens; Marie-Ange Demoitie; Patrice M Dubois; Tonya Villafana; Erik Jongert; Aurelie Olivier; Joe Cohen; Meral Esen; Peter G Kremsner; Bertrand Lell; Benjamin Mordmüller
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

7.  Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei.

Authors:  Elisa O Vintiñi; Marcela S Medina
Journal:  BMC Immunol       Date:  2011-08-11       Impact factor: 3.615

8.  Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans.

Authors:  Anne C Teirlinck; Matthew B B McCall; Meta Roestenberg; Anja Scholzen; Rob Woestenenk; Quirijn de Mast; Andre J A M van der Ven; Cornelus C Hermsen; Adrian J F Luty; Robert W Sauerwein
Journal:  PLoS Pathog       Date:  2011-12-01       Impact factor: 6.823

Review 9.  Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.

Authors:  Philippe Moris; Erik Jongert; Robbert G van der Most
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

10.  Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.

Authors:  Walter R Weiss; Anita Kumar; George Jiang; Jackie Williams; Anthony Bostick; Solomon Conteh; David Fryauff; Joao Aguiar; Manmohan Singh; Derek T O'Hagan; Jeffery B Ulmer; Thomas L Richie
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.